The Effects of Craving and Abstinence From Cigarettes on Brain Metabolism in Smokers - Full Text View

Purpose

Craving and withdrawal from smoking cigarettes are major factors for relapse. We investigated craving for cigarettes in smokers undergoing pharmacological treatment with Bupropion (Zyban). We compare cue-induced reactivity to smoking videos in smokers who were successfully treated with Bupropion to smokers who are still smoking. We measured the brain's metabolic activity in response to smoking and neutral cues in Positron Emission Tomography using FDG.

Condition	Intervention
Nicotine Dependence	Drug: Bupropion (Zyban)

MedlinePlus related topics:

Smoking

Drug Information available for:

Bupropion hydrochloride Bupropion Nicotine polacrilex Nicotine tartrate

U.S. FDA Resources

Study Type:	Interventional
Study Design:	Treatment, Non-Randomized, Open Label, Uncontrolled, Single Group Assignment, Pharmacodynamics Study

Official Title:	The Effects of Craving and Abstinence From Cigarettes on Brain Metabolism in Smokers.

Further study details as provided by Tel-Aviv Sourasky Medical Center:

Primary Outcome Measures:

Brain metabolic activity (FDG) in response to craving and neutral cues. [ Time Frame: 30-40 minutes ] [ Designated as safety issue: No ]

Secondary Outcome Measures:

Subjective ratings of craving [ Time Frame: 10 minutes ] [ Designated as safety issue: No ]

Enrollment:	24
Study Start Date:	July 2004
Study Completion Date:	October 2007
Primary Completion Date:	October 2007 (Final data collection date for primary outcome measure)

Intervention Details:

1 tablet a day increasing to 2 tablets a day after a week

Detailed Description:

Craving and withdrawal from smoking cigarettes are major factors for relapse. We investigated craving for cigarettes in smokers undergoing pharmacological treatment with Bupropion (Zyban)for 2 months. We compare cue-induced reactivity to smoking videos in smokers who were successfully treated with Bupropion to smokers who are still smoking. We measured the brain's metabolic activity after exposure to videotapes showing smoking and neutral scenes in Positron Emission Tomography using FDG. There were 2 scanning sessions, one with a smoking videotape and one with a neutral video separated by a week. So far we have compared the brain's metabolic activity in 6 abstinent smokers and 6 still smokers.

Eligibility

Ages Eligible for Study:	20 Years to 65 Years
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	Yes

Criteria

Inclusion Criteria:

Cigarette smokers (over 1 pack a day)
Age 20-65, male-females

Exclusion Criteria:

Dependence on other substances
Psychiatric diagnosis
Neurological disorder
Obesity
Young persons
Pregnant women

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00267813

Locations


Israel
	Department of Nuclear Medicine
	Tel Aviv, Israel, 64239

Sponsors and Collaborators

Tel-Aviv Sourasky Medical Center

Investigators


Principal Investigator:	Einat Even-Sapir, M.D, Ph.D	Tel-Aviv Sourasky Medical Center

Principal Investigator:	Aviv M Weinstein, Ph.D	Tel-Aviv Sourasky Medical Center

Study Director:	Hedva Lerman, M.D	Tel-Aviv Sourasky Medical Center

More Information

Responsible Party:	Sourasky Medical Center Tel Aviv ( Dr. Aviv M. Weinstein )
Study ID Numbers:	TASMC-O5-EE-065-CTIL
First Received:	December 20, 2005
Last Updated:	May 6, 2008
ClinicalTrials.gov Identifier:	NCT00267813
Health Authority:	Israel: Israeli Health Ministry Pharmaceutical Administration

Keywords provided by Tel-Aviv Sourasky Medical Center:

craving

nicotine

imaging

FDG

PET

smoking

Bupropion

Study placed in the following topic categories:

Nicotine polacrilex

Smoking

Dopamine

Nicotine

Mental Disorders

Tobacco Use Disorder

Bupropion

Substance-Related Disorders

Disorders of Environmental Origin

Additional relevant MeSH terms:

Dopamine Uptake Inhibitors

Neurotransmitter Uptake Inhibitors

Neurotransmitter Agents

Molecular Mechanisms of Pharmacological Action

Therapeutic Uses

Physiological Effects of Drugs

Psychotropic Drugs

Dopamine Agents

Antidepressive Agents, Second-Generation

Central Nervous System Agents

Pharmacologic Actions

Antidepressive Agents

ClinicalTrials.gov processed this record on November 30, 2008

Sponsored by:	Tel-Aviv Sourasky Medical Center
Information provided by:	Tel-Aviv Sourasky Medical Center
ClinicalTrials.gov Identifier:	NCT00267813